[CAS NO. 846557-71-9] ML385
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [846557-71-9]
Catalog
SLK-S8790
Brand
Selleck
CAS
846557-71-9
DESCRIPTION [846557-71-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 511.59 |
| Molecular Formula | C29H25N3O4S |
| SMILES | O=C(NC1=NC(C2=CC=C(N(C(C3=C(C)C=CC=C3)=O)CC4)C4=C2)=C(C)S1)CC5=CC(OCO6)=C6C=C5 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9547 mL | 9.7735 mL | 19.5469 mL |
| 5 mM | 0.3909 mL | 1.9547 mL | 3.9094 mL |
| 10 mM | 0.1955 mL | 0.9773 mL | 1.9547 mL |
| 50 mM | - | - | - |
Description
ML385 is a novel and specific inhibitor with an IC50 of 1.9 μM. It inhibits the downstream target gene expression of NRF2. NRF2 regulates the activity of several and lipid peroxidation-related proteins.
In vitro
ML385 shows anti-tumor activity in NSCLC (subcutaneous and orthotopic NSCLC models) both as a single agent and in combination with carboplatin. The PK profile tested in CD-1 mice shows that ML385 has a half-life (t = 2.82 h) after IP injection (30 mg/kg). ML385 could alleviate the pancreatic injury.
References
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.